查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924682

吸入式SEVOFLURANE麻醉劑市場按產品類型、應用、最終用戶和分銷管道分類－2026-2032年全球預測

Inhalation Sevoflurane Anesthesia Drugs Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，吸入式SEVOFLURANE麻醉劑市場價值將達到 12.8 億美元，到 2026 年將成長至 13.9 億美元，到 2032 年將達到 24.3 億美元，複合年成長率為 9.62%。

關鍵市場統計數據
基準年 2025 12.8億美元
預計年份：2026年 13.9億美元
預測年份 2032 24.3億美元
複合年成長率 (%) 9.62%

本文簡要概述了現代SEVOFLURANE麻醉領域的臨床意義、供應趨勢和策略影響。

吸入麻醉劑SEVOFLURANE因其優異的藥物動力學特性、可預測的起效和恢復特性以及與多種給藥系統的兼容性，仍然是現代麻醉實踐中的核心藥物。本執行摘要了近期影響SEVOFLURANE的臨床趨勢、供應鏈發展、產品創新和監管動態。它闡述了臨床需求、技術變革和政策轉變如何共同影響醫院、門診機構和其他醫療機構的籌資策略。

製劑、法律規範、通路和臨床應用方面的重大模式轉移正在重塑SEVOFLURANE的供應和採購格局。

過去幾年，受製劑技術、給藥方式和臨床需求的創新驅動，SEVOFLURANE市場格局發生了翻天覆地的變化。隨著麻醉場所從傳統手術室擴展到門診手術中心和家庭麻醉支持，麻醉劑的分銷模式也從散裝液體轉向更便捷的即用型產品，促使生產商投資研發與現代麻醉給藥系統兼容的預填充式注射器和蒸發器藥筒。

美國新關稅調整對SEVOFLURANE市場的影響，包括籌資策略重組、供應商選擇和供應鏈彈性規劃。

2025年，美國提高關稅的實施為依賴進口的SEVOFLURANE供應鏈環節帶來了額外的成本考量，促使採購和生產策略做出顯著調整。進口商和經銷商試圖透過重新評估定價結構、重新談判供應合約以及加快與國內生產商的諮詢來降低關稅波動帶來的風險。因此，醫院和門診中心的採購部門越來越傾向於選擇具備本地生產能力和透明落地成本模式的供應商。

綜合細分分析揭示了臨床應用、最終用戶概況、產品形式和分銷管道如何共同定義了SEVOFLURANE的需求概況。

要了解SEVOFLURANE市場，需要深入理解臨床應用、終端用戶、產品類型和分銷管道如何相互作用，從而影響其供需特徵。在應用方面，七氟烷的應用場景多種多樣，包括門診麻醉；全身麻醉（又細分為心臟手術、住院手術和神經外科手術）；兒童麻醉（分為日間護理和住院兩種）；以及獸醫用途，每種用途都有其獨特的操作、劑量和採購要求。在終端使用者方面，SEVOFLURANE供應給門診手術中心、診所、居家醫療機構和醫院，這些機構又可進一步細分為政府機構和私人機構，它們在採購政策、預算週期和法律規範存在差異。

從區域觀點審視美洲、歐洲、中東和非洲以及亞太地區的監管差異、臨床應用模式和供應鏈設計至關重要。

區域趨勢對SEVOFLURANE的臨床應用、監管路徑和供應鏈結構具有決定性影響。在美洲，成熟的醫院系統和廣泛的門診網路推動了對散裝和即用型七氟烷的穩定需求，而成熟的採購流程和大規模集團採購組織的存在則影響著談判能力和供應連續性策略。在歐洲、中東和非洲地區，不同的法規環境和國內生產能力的不均衡分配，需要採取差異化的分銷方式。有些市場傾向於集中競標，而有些市場則由區域分銷商來彌補物流和合規方面的不足。

製造卓越性、經銷夥伴和產品供應創新等策略競爭因素正在重新定義企業在SEVOFLURANE市場的定位。

SEVOFLURANE市場的競爭格局主要取決於製造商的大規模生產能力、配方技術、品管系統和分銷管道。投資於經過檢驗的無菌生產線、完善的品質保證流程和多樣化的包裝方案的公司，更有能力滿足醫院藥房和門診醫療機構的需求。此外，與分銷網路和醫院系統建立策略合作夥伴關係，可以提高產品知名度，並推動即用型製劑的普及。投資與蒸發器相容的藥筒和預填充給藥系統正成為差異化優勢，尤其是在手術室吞吐量和污染控制至關重要的環境中。

為製造商、醫療服務提供者和採購主管提供切實可行的策略建議，以最佳化供應鏈彈性、臨床應用和商業性成果。

產業領導者應採取多管齊下的策略，兼顧臨床偏好、供應彈性以及不斷變化的採購模式。首先，應優先投資於即用型給藥系統，例如預填充式注射器和與蒸發器相容的藥筒，以滿足門診護理和高通量手術環境的需求，因為在這些環境中，速度和無菌性至關重要。其次，應實現製造地和採購管道的多元化，以減少對單一供應商的依賴，並降低關稅和地緣政治風險。第三，應加強與醫院藥局的合作，提供以結果為導向的服務模式，包括產品操作訓練、一次性使用方案和庫存最佳化通訊協定。

為了確保研究結果的可靠性和可操作性，我們採用了嚴格的混合方法研究設計，結合了主要臨床訪談、有針對性的次要研究和檢驗通訊協定。

本執行摘要的研究採用了混合方法，結合了初步訪談、有針對性的二手資料研究和交叉檢驗，以確保研究結果的可靠性。一級資訊來源包括與臨床麻醉醫師、醫院藥屋主任、門診和住院採購人員以及供應鏈經理的結構化訪談，旨在深入了解藥物儲存、配製和給藥方面的實際挑戰。二手資料分析則納入了監管指南、生產最佳實踐和已發表的臨床文獻，以闡明實際操作情況和產品設計考量。

將臨床連續性和商業性轉型結合，凸顯了產品設計、製造韌性和分銷靈活性的內在一致性。

對SEVOFLURANE市場的全面分析凸顯了其在商業性和營運方面發生的顯著變化，以及穩定的臨床需求。臨床醫生仍然重視SEVOFLURANE可預測的藥理特性，儘管通路和產品形式有所變化，但這種臨床偏好仍然支撐著其採購優先順序。同時，從關稅帶來的成本壓力到對即用型給藥系統日益成長的需求，各種商業性因素正在重塑醫療機構採購和使用這種麻醉劑的方式。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 吸入式SEVOFLURANE麻醉劑市場（依產品類型分類）

  • 散裝液體
  • 即用型

9. 吸入式SEVOFLURANE麻醉劑市場依應用領域分類

  • 門診麻醉
  • 全身麻醉
    • 心臟手術
    • 醫院手術
    • 神經外科
  • 兒童麻醉
    • 日托
    • 住院病人
  • 獸醫護理

10. 吸入式SEVOFLURANE麻醉劑市場（依最終用戶分類）

  • 門診手術中心
  • 診所
  • 居家醫療機構
  • 醫院
    • 公立醫院
    • 私立醫院

11. 吸入式SEVOFLURANE麻醉劑市場依分銷管道分類

  • 離線
  • 線上

12. 各地區吸入式SEVOFLURANE麻醉劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 吸入式SEVOFLURANE麻醉劑市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國吸入式七SEVOFLURANE麻醉劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國吸入式SEVOFLURANE麻醉劑市場

第16章：中國吸入式七SEVOFLURANE麻醉劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Anhil Parenterals Pvt. Ltd.
  • AstraZeneca plc
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Gujarat Medicraft Private Limited
  • Halocarbon Life Sciences, LLC
  • Hikma Pharmaceuticals PLC
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Lunan Pharmaceutical Group Co., Ltd.
  • Maruishi Pharmaceutical Co., Ltd.
  • Mylan NV
  • Neon Laboratories Ltd.
  • Novartis AG
  • Piramal Enterprises Ltd.
  • Questus Pharma Pvt. Ltd.
  • Shanghai Hengrui Pharmaceutical Co., Ltd.
  • Troikaa Pharmaceuticals Ltd.
Product Code: MRR-7A380DA7C420

The Inhalation Sevoflurane Anesthesia Drugs Market was valued at USD 1.28 billion in 2025 and is projected to grow to USD 1.39 billion in 2026, with a CAGR of 9.62%, reaching USD 2.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.28 billion
Estimated Year [2026] USD 1.39 billion
Forecast Year [2032] USD 2.43 billion
CAGR (%) 9.62%

Concise overview of the clinical relevance, supply dynamics, and strategic implications defining the contemporary sevoflurane anesthesia environment

The inhalational anesthetic sevoflurane remains a core agent in contemporary anesthesia practice due to its favorable pharmacokinetic profile, predictable onset and recovery characteristics, and compatibility with a wide range of delivery systems. This executive summary synthesizes recent clinical trends, supply chain dynamics, product innovations, and regulatory developments shaping the sevoflurane landscape. It contextualizes how clinical demand, technology shifts, and policy changes are converging to influence procurement strategies in hospitals, outpatient facilities, and alternative care settings.

Across care environments, clinicians continue to prioritize agents that offer rapid titratability, hemodynamic stability, and efficient recovery, and sevoflurane often meets these clinical desiderata. At the same time, manufacturers and providers are adapting to evolving expectations for ready-to-use formats and optimized supply chains. This summary outlines the most consequential inflection points and offers a clear vantage for stakeholders to align operational, clinical, and commercial planning. By underscoring strategic levers and practical implications, the content prepares clinical leaders, procurement teams, and product strategists to respond effectively to immediate challenges and emerging opportunities.

Significant paradigm shifts in formulation, regulatory oversight, distribution channels, and clinical use that are reshaping sevoflurane delivery and procurement

Over the past several years, the sevoflurane landscape has experienced transformative shifts driven by innovations in formulation, delivery formats, and clinical expectations. Transitioning from bulk liquid distribution to more convenient ready-to-use formats has accelerated as care settings broaden beyond the traditional operating room into ambulatory surgical centers and home-based anesthesia support, prompting manufacturers to invest in prefilled syringes and vaporizer cartridges compatible with modern anesthesia delivery systems.

Concurrently, regulatory focus on sterility assurance and labeling clarity has prompted revisions to manufacturing controls and packaging standards, encouraging more stringent quality oversight. This regulatory tightening has gone hand in hand with supply chain reconfiguration: companies are diversifying manufacturing footprints and reinforcing cold-chain and controlled-handling processes to reduce single-source vulnerabilities. Clinically, the push toward enhanced recovery protocols and shorter turnover times has increased demand for agents that facilitate rapid emergence, benefiting sevoflurane's clinical positioning. Finally, distribution strategies are evolving; hospital pharmacies, direct tenders, and e-pharmacy platforms are each reshaping how sevoflurane is procured and stocked, which in turn affects pricing negotiation, inventory management, and contingency planning for high-volume institutions.

How newly implemented United States tariff adjustments have restructured procurement tactics, supplier preferences, and supply chain resilience planning in the sevoflurane market

In 2025 the imposition of increased tariffs in the United States introduced an additional layer of cost consideration for import-dependent segments of the sevoflurane supply chain, prompting visible adjustments across procurement and manufacturing strategies. Importers and distributors responded by reassessing price structures, renegotiating supply agreements, and accelerating discussions with domestic manufacturers to mitigate exposure to tariff volatility. Consequently, procurement teams at hospitals and ambulatory centers began to place a higher premium on suppliers with local or regional manufacturing capabilities and transparent landed cost models.

Tariffs have also catalyzed strategic hedging behaviors among manufacturers, leading some to reconfigure supply routes and inventory staging practices. In parallel, service providers and group purchasing organizations sharpened contractual clauses to distribute tariff risk more equitably among stakeholders. Clinicians and pharmacy directors have observed shifts in supplier diversity, with an increasing preference for vendors capable of guaranteeing supply continuity under variable tariff regimes. While these measures do not alter clinical guidelines for sevoflurane use, they do shape the commercial calculus for institutions balancing cost containment with the imperative to maintain uninterrupted access to clinically preferred anesthetic agents.

Integrated segmentation insights revealing how clinical applications, end-user profiles, product formats, and distribution channels collectively define sevoflurane demand characteristics

Understanding the sevoflurane market requires a nuanced view of how clinical applications, end users, product types, and distribution channels interact to shape demand and supply characteristics. By application, use cases span ambulatory anesthesia, general anesthesia with subdivisions for cardiac surgery, inpatient surgery, and neurosurgery, pediatric anesthesia segmented into day care and inpatient contexts, and veterinary applications, each presenting distinct handling, dosing, and procurement requirements. By end user, sevoflurane serves ambulatory surgical centers, clinics, home care settings, and hospitals, with hospitals further differentiated between government and private institutions that exhibit divergent purchasing policies, budget cycles, and regulatory oversight.

Product type segmentation differentiates bulk liquid presentations and ready-to-use formats. Bulk liquid typically arrives in 250 ml or 500 ml bottles intended for centralized pharmacy compounding and vaporizer filling, whereas ready-to-use options include prefilled syringes and vaporizer cartridges designed to reduce preparation time and contamination risk. Distribution channels encompass direct tender processes, hospital pharmacy procurement, online pharmacy platforms, and retail pharmacy points of sale, with retail further split across chain and independent pharmacies that vary in procurement scale and service level agreements. These intersecting dimensions influence inventory norms, cold-chain and sterility controls, clinician preferences, and the economics of conversion from bulk to ready-to-use solutions, thereby guiding product development and commercial positioning.

Compelling regional perspectives on regulatory nuance, clinical adoption patterns, and supply chain design across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a decisive influence on clinical adoption, regulatory pathways, and supply chain architecture for sevoflurane. In the Americas, mature hospital systems and extensive ambulatory networks drive steady demand for both bulk and ready-to-use formats, while procurement sophistication and the presence of large group purchasing organizations shape negotiation leverage and supply continuity strategies. In Europe, Middle East & Africa, heterogeneous regulatory environments and variable access to domestic manufacturing capacity necessitate differentiated distribution approaches, with some markets favoring centralized tenders and others relying on regional distributors to bridge logistics and compliance gaps.

Across the Asia-Pacific region, rapid expansion of surgical infrastructure, growing volumes of day-case procedures, and increasing attention to perioperative efficiency are accelerating uptake of ready-to-use delivery formats and vaporizer-compatible cartridges. Each region presents unique regulatory, logistical, and clinical practice nuances that affect lead times, packaging preferences, and vendor selection. Stakeholders must therefore adapt commercial models to the regulatory cadence and procurement culture of each geography, aligning supply chain investments with regional demand patterns and the evolving clinical emphasis on fast recovery and operational throughput.

Strategic competitive factors including manufacturing excellence, distribution partnerships, and product delivery innovation that are redefining players' positioning in the sevoflurane arena

Competitive dynamics in the sevoflurane space are shaped by manufacturers' capabilities in scale manufacturing, formulation expertise, quality systems, and distribution reach. Firms that invest in validated sterile production lines, robust quality assurance processes, and versatile packaging options are better positioned to meet the dual demands of hospital pharmacies and ambulatory providers. Moreover, strategic partnerships with distribution networks and hospital systems enhance product visibility and facilitate adoption of ready-to-use formats. Investment in vaporizer-compatible cartridges and prefilled delivery systems is becoming a differentiator, particularly where operating room throughput and contamination control are prioritized.

Beyond manufacturing capabilities, companies that proactively engage with regulatory authorities and clinical stakeholders to support post-market surveillance and education initiatives build trust and reduce friction in uptake. In addition, entities focused on supply chain transparency-providing clear traceability, batch-level documentation, and responsive logistics-tend to secure longer-term contracts with large institutional buyers. Private equity activity and M&A among mid-sized suppliers are also reshaping the competitive map, as consolidation enables scaling of sterile manufacturing assets and broader geographic distribution networks. Ultimately, success depends on aligning product innovation with operational realities of end users and the evolving expectations of procurement stakeholders.

Actionable strategic recommendations for manufacturers, healthcare providers, and procurement leaders to optimize supply resilience, clinical adoption, and commercial outcomes

Industry leaders should adopt a multi-pronged strategy that addresses clinical preferences, supply resilience, and evolving procurement models. First, prioritize investments in ready-to-use delivery systems such as prefilled syringes and vaporizer-compatible cartridges to accommodate ambulatory and high-throughput surgical settings where speed and sterility matter most. Second, diversify manufacturing and sourcing footprints to reduce reliance on single-source suppliers and to mitigate tariff exposure and geopolitical risk. Third, strengthen hospital pharmacy collaborations by offering outcome-oriented service models that include education on product handling, single-use options, and inventory optimization protocols.

In parallel, companies and health systems should enhance traceability and transparency across the supply chain, delivering batch-level documentation and predictable lead times to procurement teams. Engagement with regulatory bodies should be proactive, focusing on demonstrating robust sterility controls and post-market surveillance to preempt compliance challenges. Finally, consider subscription-style or value-based contracting arrangements that align supplier incentives with institutional goals for availability, cost predictability, and patient throughput. Taken together, these measures create a resilient, clinically attuned approach that balances operational efficiency with the imperative of uninterrupted access to preferred anesthetic agents.

Rigorous mixed-methods research design integrating primary clinical interviews, targeted secondary review, and triangulation protocols to ensure reliable and actionable insights

The research underpinning this executive summary employed a mixed-methods approach combining primary interviews, targeted secondary research, and cross-validation to ensure robust findings. Primary inputs included structured discussions with clinical anesthesiologists, hospital pharmacy directors, procurement leaders from ambulatory and inpatient settings, and supply chain managers, enabling direct insight into practical challenges of storage, preparation, and administration. Secondary analysis incorporated regulatory guidance, manufacturing best practices, and public domain clinical literature to contextualize operational realities and product design considerations.

Data triangulation was used to reconcile divergent stakeholder perspectives and to surface consistent themes such as the preference for ready-to-use formats in high-throughput environments and heightened concern for supply continuity under tariff-driven cost pressures. Quality controls included source verification, timestamped interview logs, and a sensitivity review with external clinical advisors to ensure clinical assertions were aligned with accepted practice. Wherever quantitative datasets were referenced, methodological caveats were applied to preserve clarity regarding data provenance and to avoid extrapolation beyond validated evidence. This methodological rigor supports actionable, defensible conclusions that stakeholders can use to inform procurement, product development, and operational planning.

Synthesis of clinical continuity and commercial transformation highlighting the essential alignment of product design, manufacturing resilience, and distribution agility

The cumulative picture of the sevoflurane landscape emphasizes stability in clinical demand alongside notable commercial and operational evolution. Clinicians continue to value sevoflurane for its predictable pharmacologic characteristics, and this clinical preference anchors procurement priorities even as distribution channels and product formats shift. Simultaneously, commercial forces-ranging from tariff-driven cost pressures to a growing appetite for ready-to-use delivery systems-are reshaping the ways in which institutions source and administer this anesthetic.

For healthcare leaders and manufacturers alike, the imperative is to align product design, manufacturing resilience, and distribution agility with the clinical workflow realities of modern perioperative care. By doing so, stakeholders can sustain clinical excellence while reducing exposure to supply disruption and cost volatility. The conclusion underscores a clear imperative: integrate clinical input into commercial strategy, invest in diversified and validated manufacturing, and pursue distribution models that reflect the operational priorities of end users to secure reliable access to sevoflurane across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Inhalation Sevoflurane Anesthesia Drugs Market, by Product Type

  • 8.1. Bulk Liquid
  • 8.2. Ready To Use

9. Inhalation Sevoflurane Anesthesia Drugs Market, by Application

  • 9.1. Ambulatory Anesthesia
  • 9.2. General Anesthesia
    • 9.2.1. Cardiac Surgery
    • 9.2.2. Inpatient Surgery
    • 9.2.3. Neurosurgery
  • 9.3. Pediatric Anesthesia
    • 9.3.1. Day Care
    • 9.3.2. Inpatient
  • 9.4. Veterinary

10. Inhalation Sevoflurane Anesthesia Drugs Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Home Care Settings
  • 10.4. Hospitals
    • 10.4.1. Government Hospitals
    • 10.4.2. Private Hospitals

11. Inhalation Sevoflurane Anesthesia Drugs Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Inhalation Sevoflurane Anesthesia Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Inhalation Sevoflurane Anesthesia Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Inhalation Sevoflurane Anesthesia Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Inhalation Sevoflurane Anesthesia Drugs Market

16. China Inhalation Sevoflurane Anesthesia Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Anhil Parenterals Pvt. Ltd.
  • 17.8. AstraZeneca plc
  • 17.9. B. Braun Melsungen AG
  • 17.10. Baxter International Inc.
  • 17.11. Fresenius Kabi AG
  • 17.12. Gujarat Medicraft Private Limited
  • 17.13. Halocarbon Life Sciences, LLC
  • 17.14. Hikma Pharmaceuticals PLC
  • 17.15. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 17.16. Lunan Pharmaceutical Group Co., Ltd.
  • 17.17. Maruishi Pharmaceutical Co., Ltd.
  • 17.18. Mylan N.V.
  • 17.19. Neon Laboratories Ltd.
  • 17.20. Novartis AG
  • 17.21. Piramal Enterprises Ltd.
  • 17.22. Questus Pharma Pvt. Ltd.
  • 17.23. Shanghai Hengrui Pharmaceutical Co., Ltd.
  • 17.24. Troikaa Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY BULK LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY BULK LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY BULK LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY READY TO USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY READY TO USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY READY TO USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CARDIAC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CARDIAC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CARDIAC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY NEUROSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY NEUROSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY NEUROSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DAY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DAY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DAY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY VETERINARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY VETERINARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 144. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 145. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 168. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 169. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 176. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 177. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY GENERAL ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY PEDIATRIC ANESTHESIA, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA INHALATION SEVOFLURANE ANESTHESIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)